Pantoprazole is a selective proton pump inhibitor drug (PPI) used for short-term treatment of erosion and ulceration of the esophagus caused by Gastroesophageal reflux disease. It acts by inhibiting the secretion of hydrochloric acid in the stomach by specific action on proton pumps of parietal cells.


Pantoprazole is used for relieving the symptoms and for the short term treatment of gastrointestinal diseases:
♦ Duodenal ulcer
♦ Gastric ulcer
♦ Gastro-esophageal reflux disease
♦ Moderate and severe reflex oesophagitis
♦ Zollinger-Ellison syndrome and other hypersecretory conditions
♦ Prevention of gastro duodenal ulcers induced by non-selective non-steroidal anti-inflammatory drugs (NSAIDs)



Pantoprazole is a proton pump inhibitor. It inhibits specifically and dose-proportionately H+/K+-ATPase, the enzyme which is responsible for gastric acid secretion in the parietal cells of the stomach. Pantoprazole's selectivity is due to the fact that it only exerts its full effect in a strongly acidic environment (pH < 3), remaining mostly inactive at higher pH values. As a result, its complete pharmacological, and thus therapeutic effect, can only be achieved in the acid secretory parietal cells. By means of a feedback mechanism this effect is diminished at the same rate as acid secretion is inhibited.


Absorption: Well absorbed; peak plasma concentrations: Approx 2-2.5 hr after oral dose & Oral bioavailability is Approx 77%.
Distribution: Protein-binding: 98%; volume of distribution: 11-24 L.
Metabolism: Hepatic; mainly by cytochrome CYP2C19 and slightly by CYP2D6 and CYP2C0.
Excretion: Via urine (approx 80%) and bile (approx 20%).
Elimination Half Life: Approx 1 hour (prolonged in hepatic impairment; in patients with cirrhosis the elimination half life may be 3-10 hours)


Diarrhoea, dizziness, pruritus, skin rashes, headache, nausea.


In patients with severe liver impairment the liver enzymes should be monitored regularly during treatment with Pantoprazole, particularly on long-term use. In the case of a rise of the liver enzymes Pantoprazole tablets should be discontinued.


♦ Hypersensitive to Pantoprazole to any of the ingredients.
♦ Pantoprazole like proton inhibitors should not be administered with atazanavir.

Scroll to Top ↑